Cellectar Biosciences (NASDAQ:CLRB) has partnered with Evestia Clinical to conduct a Phase 1b clinical trial for CLR 125, an iodine-125 Auger-emitting drug candidate targeting triple-negative breast cancer (TNBC). The trial is set to begin in Q4 2025 at Mayo Clinic, with Dr. Pooja Advani serving as lead investigator.Evestia Clinical, recently merged with Atlantic Research Group (ARG), will provide comprehensive CRO services, leveraging their experience from over 300 oncology studies. CLR 125 is being developed to treat various solid tumors, including triple negative breast, lung, and colorectal cancers.

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical

Cellectar (NASDAQ: CLRB) reported 2025 results and corporate updates on March 4, 2026, highlighting regulatory progress for iopofosine I-131, initiation of a Phase 1b study for CLR 125 in triple negative breast cancer, and patent and supply agreements to support its radiotherapeutic pipeline.Financials: cash of $13.2M at year-end; full-year net loss of $21.8M; R&D and G&A both ~$11.5M.

Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026 Plans to Present Final Results and

Cellectar Biosciences (NASDAQ: CLRB) announced a multi-year supply agreement with Ionetix to secure clinical- and commercial-scale cGMP-grade Actinium-225 (Ac-225) and Astatine-211 (At-211) for development of targeted alpha therapies, including the phospholipid radioconjugate CLR-225 for solid tumors.Ionetix will install a second cyclotron at its Michigan facility, with one cyclotron dedicated to Ac-225 and the other to At-211, aiming to provide a dependable, scalable isotope supply for clinical trials and potential commercial launches.

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP) Initiated Phase 1b Study of CLR 125 for TNBC Received Rare

Cellectar Biosciences (NASDAQ:CLRB) announced agreements with institutional investors resulting in the immediate exercise of existing warrants and gross proceeds of approximately $5.8 million prior to placement agent fees and offering expenses. An aggregate of 1,048,094 existing warrants were exercised.In the transactions, holders paid $5.25 per existing warrant and $0.125 per new warrant, receiving 1,048,094 Series I and 1,048,094 Series II new unregistered warrants exercisable at $6.00. Series I term: 5 years; Series II term: 18 months. Net proceeds will fund working capital, the Phase 1b CLR 121125 trial in triple-negative breast cancer, and preparation of a CMA filing with the European Medicines Agency. The company will file a registration statement covering resale of shares issuable upon exercise.

Cellectar Biosciences (NASDAQ:CLRB) has entered into a supply agreement with ITM Isotope Technologies Munich SE for Actinium-225 (Ac-225), a crucial isotope for targeted cancer therapies. The agreement will support the clinical development of Cellectar's CLR 121225, a Phase 1-ready compound for treating solid tumors, particularly pancreatic cancer.The partnership addresses the critical challenge of Ac-225 scarcity in radiopharmaceutical development. ITM, through its joint venture Actineer with Canadian Nuclear Laboratories, will provide Cellectar with medical-grade Ac-225. CLR 121225 has shown promising anti-tumor effects in preclinical studies, utilizing Cellectar's proprietary phospholipid ether (PLE) delivery platform for selective cancer cell targeting.

Cellectar Biosciences (NASDAQ:CLRB) reported Q2 2025 financial results and provided significant updates on its radiopharmaceutical pipeline. The company plans to pursue an FDA NDA submission for iopofosine I 131 to treat Waldenstrom Macroglobulinemia (WM) under accelerated approval, subject to funding and confirmatory trial initiation. The drug received FDA Breakthrough Therapy Designation for WM treatment.Key financial metrics include cash position of $11.0 million as of June 30, 2025, with an additional $5.8 million raised in July 2025. R&D expenses decreased to $2.4 million from $7.3 million year-over-year, while Q2 net loss was $5.4 million. The company expects current funding to support operations into Q2 2026.In pediatric high-grade glioma trials, patients receiving minimum dosing showed 5.4 months progression-free survival and 8.6 months overall survival. The company plans to advance CLR 125 into Phase 1 TNBC trials by Q4 2025.

Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer drug development, has announced the pricing of an underwritten public offering to raise approximately $6 million in gross proceeds.The offering consists of 865,000 Class A Units at $5.00 per unit (including one common stock share and one common warrant) and 335,000 Class B Units at $4.99999 per unit (including one pre-funded warrant and one common warrant). The common warrants will have an exercise price of $5.25 per share with a five-year term.The company plans to use the proceeds for general corporate purposes, working capital, and to initiate a Phase 1b clinical study of CLR 121125 (CLR 125) in triple-negative breast cancer. Ladenburg Thalmann & Co. Inc. is serving as the sole bookrunning manager, with the offering expected to close around July 2, 2025.

Cellectar Biosciences (NASDAQ: CLRB) has entered into a multi-year supply agreement with Nusano for the provision of iodine-125 (I-125) and actinium-225 (Ac-225) isotopes. The partnership will support Cellectar's radiotherapeutic pipeline development, including CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer.The isotopes will be produced at Nusano's next-generation facility in Utah, ensuring uninterrupted access to these essential materials for both clinical development and future commercial needs. This strategic partnership addresses critical supply chain challenges in the production of rare medical radioisotopes at commercial scale.

Cellectar Biosciences (NASDAQ:CLRB) has submitted a protocol to the FDA for a Phase 1b dose-finding study of CLR 125, an Auger-emitting radiopharmaceutical for treating triple-negative breast cancer (TNBC). The study will evaluate three different dosing regimens across 15 patients per arm, totaling 45 patients.The trial aims to determine the recommended Phase 2 dose, assess safety and tolerability, and evaluate initial response using RECIST criteria and progression-free survival. CLR 125 showed promising preclinical results, demonstrating good tolerability and robust tumor uptake in TNBC animal models. The drug leverages the company's PDC-targeted delivery platform to deliver iodine-125 directly to cancer cell nuclei and mitochondria.

Cellectar Biosciences (CLRB) has announced a 1-for-30 reverse stock split effective June 24, 2025, at 12:01 a.m. Eastern Time. The company's stock will continue trading on Nasdaq under the same symbol with a new CUSIP number 15117F880. This corporate action will reduce outstanding shares from 54,361,197 to approximately 1,812,040. The split was approved by stockholders on June 13, 2025, and will not alter stockholders' ownership percentages except for fractional shares, which will be paid in cash. The reverse split will proportionally adjust equity incentive plans, outstanding stock options, warrants, and preferred stock conversion ratios. Equiniti Trust Company will manage the split process, with no action required from stockholders holding shares either directly or through brokers.

Cellectar Biosciences announced promising initial results from their CLOVER-2 Phase 1 trial of iopofosine I 131 in treating pediatric high-grade glioma (pHGG). Patients receiving a minimum 55 mCi dose (n=7) showed average progression-free survival (PFS) of 5.4 months, more than double the typical 2.25 months median. Overall survival reached 8.6 months, surpassing the standard 5.6 months. Notably, patients receiving four or more infusions (n=3) achieved 8.1 months PFS and 11.5 months overall survival, with two patients showing objective responses. The drug demonstrated good tolerability with manageable side effects, primarily hematologic in nature, with no cardiovascular, renal, liver toxicities, peripheral neuropathy, or significant bleeding reported.

Cellectar Biosciences (NASDAQ: CLRB) has announced agreements to raise $2.5 million through the sale of common stock at market price. The deal involves immediate exercise of outstanding warrants for 8,301,322 shares at a reduced price of $0.3041 per share. These warrants were previously issued between 2020-2024. The offering is expected to close around June 6, 2025, with Ladenburg Thalmann & Co. Inc. serving as exclusive placement agent. The company plans to use the net proceeds for general corporate purposes, including working capital and operating expenses. All shares issuable through warrant exercise are registered or have registered resale under effective registration statements.

Cellectar Biosciences (NASDAQ: CLRB) has received FDA Breakthrough Therapy Designation for iopofosine I 131, a potential first-in-class cancer targeting agent, for treating relapsed/refractory Waldenstrom macroglobulinemia (WM). The designation is supported by impressive Phase 2 CLOVER WaM study results, showing an 83.6% overall response rate and 58.2% major response rate, significantly exceeding the primary endpoint target of 20% MRR. The drug has already secured FDA Fast Track and Orphan Drug Designations, along with EMA Orphan Drug and PRIME Designations. Cellectar has submitted data to the EMA for potential fast-track, conditional marketing authorization, with a response expected in late July 2025. This development represents a significant advancement for WM patients, as current treatment options are limited and the condition remains incurable.

Cellectar Biosciences (NASDAQ: CLRB) reported Q1 2025 financial results and provided corporate updates. The company plans to seek conditional approval from EMA for Iopofosine I 131 in treating Waldenstrom Macroglobulinemia, with Phase 2 CLOVER WaM study showing a 59.0% major response rate in BTKi-treated patients. The company reported cash and equivalents of $13.9 million, down from $23.3 million in December 2024, sufficient to fund operations into Q4 2025. Q1 2025 saw reduced losses with net loss of $6.6 million ($0.14/share) compared to $26.6 million ($0.91/share) in Q1 2024. R&D expenses decreased to $3.4 million from $7.1 million, and G&A expenses reduced to $3.0 million from $4.9 million. The company is exploring strategic alternatives and has engaged Oppenheimer & Co. Inc. as financial advisor.

Cellectar Biosciences (NASDAQ: CLRB) has announced plans to explore strategic alternatives to maximize stockholder value. The company, which focuses on cancer drug development, is considering various options including mergers, acquisitions, partnerships, joint ventures, and licensing arrangements. The company has engaged Oppenheimer & Co as exclusive financial advisor for the strategic evaluation process. CEO James Caruso highlighted their key asset iopofosine I 131, along with alpha- and Auger-emitting radioconjugates (CLR 225 and CLR 125) for solid tumor treatments. While no specific timetable has been set for the evaluation process, Cellectar emphasizes that no agreements have been reached, and there are no guarantees that the process will result in any transaction. The company will only disclose further information when deemed necessary.

Cellectar Biosciences (NASDAQ: CLRB) reported financial results for 2024 and provided corporate updates. The company achieved FDA alignment for potential accelerated approval of iopofosine I 131 for Waldenström macroglobulinemia (WM) treatment. The Phase 2 CLOVER-WaM study showed an 83.6% Overall Response Rate and 58.2% Major Response Rate.Financial highlights include cash and equivalents of $23.3 million as of December 31, 2024, compared to $9.6 million in 2023. The company raised $44.1 million through warrant exercises in January 2024 and $19.4 million in July 2024. R&D expenses decreased to $26.1 million from $27.3 million, while G&A expenses increased to $25.6 million from $11.7 million. Net loss was $44.6 million ($1.22 per basic share).The company plans Phase 1 solid tumor studies with two radioconjugate compounds: CLR 121125 for triple-negative breast cancer and CLR 121225 for pancreatic cancer, with an IND submission planned for first half 2025.

Cellectar Biosciences reports exceptional Phase 2 results for Iopofosine I 131 in Waldenstrom's treatment, advances toward FDA approval with strong pipeline developments.

Cellectar Biosciences pivots focus to new radioconjugate programs following FDA feedback on iopofosine I 131. Company implements restructuring with workforce reduction to extend runway.